SEC Comment Letter 0000000000-23-004430 to Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Date: May 1, 2023 · CIK: 0001501756 · Accession: 0000000000-23-004430
AI Filing Summary & Sentiment
File numbers found in text: 333-271431
Letter
United States securities and exchange commission logo May 1, 2023 Linda Rubinstein Chief Financial Officer Adverum Biotechnologies, Inc. 100 Cardinal Way Redwood City, CA 94063 Re:Adverum Biotechnologies, Inc. Registration Statement on Form S-3 Filed April 25, 2023 File No. 333-271431 Dear Linda Rubinstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brett White, Esq.
Show Raw Text
United States securities and exchange commission logo
May 1, 2023
Linda Rubinstein
Chief Financial Officer
Adverum Biotechnologies, Inc.
100 Cardinal Way
Redwood City, CA 94063
Re:Adverum Biotechnologies, Inc.
Registration Statement on Form S-3
Filed April 25, 2023
File No. 333-271431
Dear Linda Rubinstein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brett White, Esq.